Breast cancer that is her2 positive is often treated with targeted drugs against her2, and cure rates vary slightly depending on the treatment. The cure rate ranges from 21.52% to 45.74%. 1. Lapatinib: the cure rate of this group is 21.52%, the control rate is 51.90%, the progression-free survival is 41 months, and the overall response rate is 56.96%. It is contraindicated in people who are allergic to the drug. Adverse reactions include nausea, vomiting, dyspepsia, dyspnea and so on. 2. Trastuzumab group: the cure rate of this group is 24.39%, the control rate is 57.32%, the progression-free survival is 43 months, and the overall response rate is 59.76%. The drug is contraindicated in those who are allergic to it and used with caution in pregnant women. Adverse reactions include headache, diarrhea, nausea and chills. 3. Combination group: the cure rate of this group is 45.74%, the control rate is 76.60%, the progression-free survival is 55 months, and the overall response rate is 76.60%. Contraindications and adverse reactions are the same as above. Drugs need to be used under the guidance of a doctor, do not blindly use drugs, need regular review during the use of drugs, monitoring blood routine, liver and kidney function and other indicators have, in order to avoid the emergence of serious adverse reactions.